Retatrutide Dosage in Clinical Trials The primary source of dosage data for retatrutide comes from the Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023)
The GLP1R cell line has been used to characterize AVPR2-modulating activities of various compound candidates, which is efficient, convenient, and flexible to multiple study formats
Sold for research use only (RUO)
Sun K, Kusminski CM, Scherer PE (2011) Adipose tissue remodeling and obesity
Retatrutide (60mg) is a synthetic investigational peptide studied in laboratory settings for its role in metabolic signaling and energy regulation research
Russell-Jones D, Vaag A, Schmitz O, et al